Related Experiment Video
Updated: Aug 13, 2026
08:34
Isolation of Atrial Myocytes from Adult Mice
Published on: July 25, 2019
B-type natriuretic peptide in ischemic heart disease
1Division of Cardiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, HA 9.133, Dallas, TX 75390-9047, USA. james.delemos@utsouthwestern.edu
Current Cardiology Reports
|June 13, 2003
Summary
B-type natriuretic peptide (BNP) and N-terminal prohormone (N-proBNP) are released by the heart under stress. BNP measurement shows promise as a prognostic marker in acute coronary syndromes (ACS), indicating worse outcomes.
Area of Science:
- Cardiology
- Biomarkers
- Heart Failure
Background:
- B-type natriuretic peptide (BNP) and N-terminal prohormone (N-proBNP) are released from the heart due to increased wall stress.
- BNP and N-proBNP assays are commercially available and increasingly used for suspected heart failure diagnosis and risk stratification.
- This review specifically examines the role of BNP and N-proBNP in patients with acute coronary syndromes (ACS).
Purpose of the Study:
- To review the emerging role of BNP and N-proBNP measurement in patients with acute coronary syndromes (ACS).
- To evaluate the diagnostic and prognostic utility of BNP and N-proBNP in the context of ACS.
Main Methods:
- Review of existing experimental and clinical studies on BNP and N-proBNP in ACS.
- Analysis of the correlation between BNP levels and clinical outcomes in ACS patients.
- Comparison of BNP's prognostic value against clinical variables, other biomarkers, and left ventricular ejection fraction.
Main Results:
- While BNP is unlikely to diagnose cardiac ischemia due to non-specific elevations, it shows significant prognostic value in ACS.
- Higher BNP levels consistently correlate with worse clinical outcomes in patients with ACS.
- BNP provides unique prognostic information beyond traditional clinical variables, biomarkers, and ejection fraction.
Conclusions:
- BNP measurement is a promising prognostic tool for patients with acute coronary syndromes (ACS).
- Further research is required to determine the therapeutic implications of elevated BNP levels in ACS management.
Related Concept Videos
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...